Atrial Fibrillation Guidelines Updated

Published Online: Thursday, April 10, 2014
Follow Pharmacy_Times:
The American Heart Association, American College of Cardiology, and Heart Rhythm Society have updated their guidelines on management of atrial fibrillation. The new guidelines include recommendations regarding use of new oral anticoagulants—dabigatran, rivaroxaban, and apixaban—as well as warfarin. However, the guidelines do not specify preferences among the 3 new oral anticoagulants due to a lack of head-to-head trials and note that treatment decisions should be based on concerns including risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics. The guidelines will be published in the Journal of the American College of Cardiology, Circulation, Journal of the American Heart Association, and Heart Rhythm.

To read more about the new guidelines on HCPLive, click here.
Related Articles
The clinical risk calculators incorporated into dyslipidemia treatment guidelines may overestimate a patient’s risk of experiencing a cardiovascular event.
A paper from a pair of physicists may reveal significant new information about the causes of atrial fibrillation and help to make cardiac ablations a more effective treatment for the condition.
Gastroesophageal reflux disease and atrial fibrillation are 2 of the most significant health concerns in the United States, and researchers suspect a link between them.
Students who pull all-nighters may want a refresher on how much sleep they should be getting each night.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$